Mining The Data: WellPoint Stresses Need For Context In Safety Surveillance
This article was originally published in The Pink Sheet Daily
WellPoint is exploring ways to more accurately identify adverse events as it builds a drug safety monitoring system.
You may also be interested in...
FDA's Sentinel post-market safety monitoring project will augment, not replace, the agency's current repertoire of post-market activities and requirements for drugs, Center for Drug Evaluation and Research Director Janet Woodcock emphasized
WellPoint is developing a post-marketing drug safety monitoring system that will be capable of drawing data from the 25 million members in its integrated medical and pharmacy insurance plans
Bipartisan congressional letters seek relief from HHS but the Trump Administration has taken aim at 340B providers itself and may not be inclined to help.